SSYS Stock Recent News

Stratasys (SSYS) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.04 per share a year ago.

Forex headwinds and divestment of certain businesses are likely to have hurt SSYS' Q2 top line despite product updates and launches.

- Recently initiated a pre-clinical trial with CollPlant's rhCollagen-based regenerative breast implants, printed with Stratasys' Origin ® 3D printer that are 200cc in volume - Breast implants could address a $3.0 billion market opportunity - Cash and cash equivalents balance as of June 30, 2024 was $18.9 million - Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel , Aug. 20, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced financial results for the second quarter ended June 30, 2024, and provided a corporate update.

3D Printed Breast implants consisting of 200cc in volume of CollPlant's rhCollagen-based bioinks produced on a Stratasys' Origin® printer to be tested Technology innovation addresses a $3.0 billion market opportunity Study to focus on ability of implants to grow natural breast tissue and completely degrade over time  REHOVOT, Israel & EDEN PRAIRIE, Minn. , Aug. 19, 2024 /PRNewswire/ -- In a significant step in the advancement of regenerative medicine, CollPlant Biotechnologies (Nasdaq: CLGN) and Stratasys Ltd.

Stratasys (SSYS) launches the latest dental 3D printer, DentaJet XL, to reduce costs and improve dental lab productivity.

EDEN PRAIRIE, Minn. & REHOVOT, Israel--(BUSINESS WIRE)--In recognition of its leadership in ESG & sustainability, Stratasys, Ltd. (NASDAQ: SSYS) was honored with four Sustainability Recognition Awards at the Additive Manufacturer Green Trade Association (AMGTA) 2024 Annual Summit in Los Angeles on June 24th. Stratasys received accolades across multiple categories, underscoring its commitment to environmental sustainability and innovation: Environmental Management Systems – For maintaining I.

Stratasys (SSYS) and Ricoh co-sponsor a clinical study comparing the efficacy of 3D-printed models to traditional CT or MRI scanning for bone tumor excision planning.

Stratasys and Ricoh co-sponsor clinical study comparing the efficacy of 3D printed models to traditional CT or MRI scanning for bone tumor excision planning EXTON, Pa. and EDEN PRAIRIE, Minn.

EDEN PRAIRIE, Minn. & REHOVOT, Israel & EXTON, Pa.--(BUSINESS WIRE)--Stratasys Ltd. (NASDAQ: SSYS) and Ricoh USA, Inc. today announced the enrollment of the first patient in a groundbreaking clinical study aimed to evaluate the use of 3D printed models for orthopedic oncology. The study will assess the efficacy of patient-specific 3D printed anatomical models for preoperative planning and tumor excision in comparison to the current standard of care, which relies solely on CT or MRI imaging. The.

Stratasys (SSYS) partners with AM Craft to expand the demand for flight-certified 3D printed parts in the aviation industry.